WHO approves emergency use of Sinofam vaccine in China... "Effective 79% estimated"

<Anchor> The

World Health Organization has approved the emergency use of the Chinese pharmaceutical company Sinoparm's COVID-19 vaccine. This is the first time a vaccine developed in a non-Western country has been approved.

Reporter Jeon Hyeong-woo reports.

<Reporter> The

World Health Organization's WHO approved the emergency use of the Corona 19 vaccine developed by Chinese pharmaceutical company Sinoparm.

With this approval, synoparm vaccine can be supplied through COVAX, an international project for joint purchase and distribution of the Corona 19 vaccine.

This is the sixth vaccine approved by the WHO, following Pfizer and AstraZeneca, India's Serum Institute, Janssen and Modena.

[Governor Yeosus/WHO Secretary General: China's Sinopam vaccine has become the 6th Corona 19 vaccine that has been verified by WHO for its safety, efficacy, and quality.]

Currently, there are 40 Sinopam vaccines in China, Hungary, and Iran. It is being used in the country.

The WHO estimates that the synopam vaccine is 79% effective for symptomatic and hospitalized patients.

The WHO is also reviewing approvals for the Sinovac vaccine in China and the Sputnik vaccine in Russia.

The New York Times reported that Pfizer has requested formal approval from the Food and Drug Administration's FDA for use of the vaccine.

It is the first time Pfizer has requested formal approval from the FDA.

Unlike emergency approval, formal approval allows Pfizer to market the vaccine directly like any other drug.

It is expected that it will take several months to become officially approved.